

DAFTAR PUSTAKA

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, Revised. NHLBI WHO. 2018.
2. Mathers CD, Loncar D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Med. 2006;3(11):2011-30
3. WHO. Chronic respiratory diseases: Burden of COPD [Online]. Tersedia di <http://www.who.int/respiratory/copd/burden/en> [Diakses pada 10 Juni 2019].
4. [RISKESDAS] Riset Kesehatan Dasar. Badan Penelitian dan Pengembangan Kesehatan, Departemen Kesehatan, Republik Indonesia. Jakarta.2013.
5. Ferrer M, Alonso J, Morera J. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med.1997;127:1072-9
6. Osman LM, Godden DJ, Friend JAR. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease.1997;52:67-71
7. Domingo-Salvany A, Lamarca R, Ferrer M. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:680-5
8. Wedzicha JA, Donaldson GC. Exacerbations of Chronic Obstructive Pulmonary Disease. RESPIRATORY CARE. 2003;48(12):223-5
9. Bahador K, Fitzgerald JM. Risk factors of hospitalization and readmission of patients with COPD exacerbation. Int J Chron Obstruct Pulmon Dis 2007; 2(3):241-51.
10. Brinke AT, Sterk PJ, Masclee AAM, Spinhoven P, Schmidt P, Zwindermane AH, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. European Respiratory Journal. 2005;26(5):812–8.
11. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. EurRespir J. 2009;33:1165-85.

12. Robalo NA, Tátá M. The impact of anaemia and iron deficiency in chronic obstructive pulmonary disease: A clinical overview. *Revista Portuguesa de Pneumologia (English Edition)*. 2017;23(3):146–55.
13. Sarkar M, Rajta P, Khatana J. Anemia in Chronic obstructive pulmonary disease: Prevalence, pathogenesis, and potential impact. *Lung India*. 2015;32(2):142-51
14. Halpern MT, Zilberberg MD, Schmier JK. Anemia, costs and mortality in chronic obstructive pulmonary disease. *Cost Eff Resour Alloc* 2006;4:1-8
15. Similowski T, Agustí A, MacNee W, Schönhofer B. The potential impact of anaemia of chronic disease in COPD. *Eur Respir J* 2006;27:390-6.
16. Shorr AF, Doyle J, Stern L, Dolgitsers M, Zilberberg MD. Anemia in chronic obstructive pulmonary disease: epidemiology and economic implications. *Current Medical Research and Opinion*. 2008;24(4):1123–30.
17. Cote C, Zilberberg MD, Mody SH, Dordelly LJ, Celli B. Haemoglobin level and its clinical impact in a cohort of patients with COPD. *Eur Respir J*. 2007; 29: 923–9
18. Similowski T, Agustí A, MacNee W, Schönhofer B. The potential impact of anaemia of chronic disease in COPD. *Eur Respir J* 2006;27:390-6.
19. Martinez-Rivera C, Portillo K, Muñoz-Ferrer A, Martínez-Ortiz ML, Molins E, Serra P. Anemia is a Mortality Predictor in Hospitalized Patients for COPD Exacerbation. *COPD: Journal of Chronic Obstructive Pulmonary Disease*. 2012 May 23;9(3):243–50.
20. Barba R, de Casasola GG, Marco J, Emilio Losa J, Plaza S, Canora J. Anemia in chronic obstructive pulmonary disease: A readmission prognosis factor. *Curr Med Res Opin* 2012;28:617-22.
21. Perhimpunan Dokter Paru Indonesia. (Penyakit Paru Obstruktif Kronik (PPOK), Diagnosis dan penatalaksanaan. PDPI. Jakarta;2011.Hal 1-86
22. Stoller JK, Aboussouan LS. α 1-antitrypsin deficiency. *Lancet* 2005;365: 2225–36

23. Kalfopoulos M, Wetmore K, ElMallah M. Pathophysiology of Alpha-1 Antitrypsin Lung Disease. Springer New York.2017;2:9–19.
24. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. The Lancet. 2006;367(9524):1747–57.
25. Reilly KH, Gu D, Duan X, Wu X, Chen C-S, Huang J, et al. Risk Factors for Chronic Obstructive Pulmonary Disease Mortality in Chinese Adults. American Journal of Epidemiology. 2008;167(8):998–1004.
26. Hnizdo E, Sullivan PA, Bang KM, Wagner G. Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2002; 156: 738–46.
27. Trupin L, Earnest G, San Pedro M. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 2003; 22:462–69.
28. Y Liu, K Lee, R Perez Padilla, NL Hudson, DM Mannino, Outdoor and indoor air pollution and COPD related disease in high and low income countries, The International Journal of Tuberculosis and Lung Disease. 2008;12(2):115-127
29. Anto JM, Vermeire P, Vestbo J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J. 2001; 17:982–94.
30. P Yin, CQ Jiang, KK Cheng. Passive smoking exposure and risk of COPD among adults in China. The Lancet. 2007;370:751-7
31. Shohaimi S, Welch A, Bingham S. Area deprivation predicts lung function independently of education and social class. Eur Respir J. 2004; 24: 157–61.
32. Lawlor DA, Ebrahim S, Davey SG. Association between self-reported childhood socioeconomic position and adult lung function: findings from the British Women's Heart and Health Study.2004;59:199–203.
33. Soriano JB, Davis KJ, Coleman B. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom.2003;124:474–81.

34. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. *Am J Respir Crit Care Med*.2001;163:1256-76
35. Di Stefano A, Caramori G, Ricciardolo FLM, Capelli A, Adcock IM, Donner CF. Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overview. *Clin Exp Allergy*.2004;34:1156– 67.
36. Spurzem JR, Rennard SI. Pathogenesis of COPD. *Seminars in respiratory and critical care medicine*. 2005; 26(2):142-53
37. Paone G, Conti V, Vestri A. Analysis of sputum markers in the evaluation of lung inflammation and functional impairment in symptomatic smokers and COPD patients. *Dis Markers*. 2011;31(2):91–100.
38. Frasca L, Lande R. Role of defensins and cathelicidin LL37 in auto-immune and auto-inflammatory diseases. *Curr Pharm Biotechnol*. 2012;13(10):1882-97.
39. Aldonyte R, Bagdonas E, Raudoniute J, Bruzauskaite I. Novel aspects of pathogenesis and regeneration mechanisms in COPD. *COPD*. 2015;10:995-1013
40. Kobayashi SD, DeLeo FR. Role of neutrophils in innate immunity: a systems biology-level approach. *Wiley Interdiscip Rev Syst Biol Med*. 2009;1(3):309-33
41. Kobayashi SD, Voyich JM, Burlak C, DeLeo FR. Neutrophils in the innate immune response. *Arch Immunol Ther Exp (Warsz)*. 2005;53(6):505–17.
42. John M, Hoernig S, Doehner W, Okonko DD, Witt C, Anker SD. Anemia and inflammation in COPD.2005;127:825-9.
43. Brashier B, Kodgule R. Risk factors and pathophysiology of chronic pulmonary disease (COPD). *J Assoc Physicians India*. 2012;60:17-21.
44. Jones PW. Health status measurement in chronic obstructive pulmonary disease.2001; 56(11): 880-7.

45. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. *Eur. Respir. J.* 2009;34(3), 648–54.
46. Jones P, Jenkins C, Bauerle O. COPD assessment test. *Healthc Prof User Guid.* 2012;34(3):1-9.
47. Ferguson GT, Enright PL, Buist AS, Higgins MW. Office Spirometry for Lung Health Assessment in Adults: A Consensus Statement from The National Lung Health Education Program. 2000;117(4):1146–61.
48. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2005; 171(9): 972-7
49. Watz H, Pitta F, Rochester CL. An official European Respiratory Society statement on physical activity in COPD. *Eur Respir J.* 2014; 44(6): 1521-37.
50. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. 2006; 61(9): 772-8.
51. Yohannes AM, Baldwin RC, Connolly M. Mortality predictors in disabling chronic obstructive pulmonary disease in old age. *Age Ageing.* 2002;31(2): 137-40.
52. Mantoani LC, Rubio N, McKinstry B, MacNee W, Rabinovich RA. Interventions to modify physical activity in patients with COPD: a systematic review. *Eur Respir J.* 2016; 48(1): 69-81.
53. Ferreira IM, Brooks D, White J, Goldstein R. Nutritional supplementation for stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2012;41-8
54. Rennard SI, Daughton D, Fujita J, et al. Short-term smoking reduction is associated with reduction in measures of lower respiratory tract inflammation in heavy smokers. *Eur Respir J.* 1990;3(7):752–9

55. Spruit MA, Singh SJ, Garvey C. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. *Am J Respir Crit Care Med*.2013; 188(8): 13-64.
56. Vogiatzis I, Rochester CL, Spruit MA, Troosters T, Clini EM, American Thoracic Society/European Respiratory Society Task Force on Policy in Pulmonary Rehabilitation. Increasing implementation and delivery of pulmonary rehabilitation: key messages from the new ATS/ERS policy statement. *Eur Respir J*.2016; 47(5): 1336-41.
57. Garvey C, Bayles MP, Hamm LF. Pulmonary Rehabilitation Exercise Prescription in Chronic Obstructive Pulmonary Disease: Review of Selected Guidelines: An official statement from the American Association of Cardiovascular and Pulmonary Rehabilitation *J Cardiopulm Rehabil Prev*. 2016; 36(2): 75-83.
58. Parveen S, Rangreze I, Ahmad SN, Mufti SA, Khan SS. Prevalence of anemia in patients with COPD and its potential impact on morbidity of COPD patients. *Int J Clin Med* 2014;5:452-8.
59. Shorr AF, Doyle J, Stern L, Dolgitsers M, Zilberberg MD. Anemia in chronic obstructive pulmonary disease: Epidemiology and economic implications. *Curr Med Res Opin*.2008;24:1123-30.
60. Chambellan A, Chailleux E, Similowski T. ANTADIR Observatory Group. Prognostic value of hematocrit in patients with severe COPD receiving long-term oxygen therapy.2005; 128: 1201–8.
61. John M, Lange A, Hoernig S, Witt C, Anker SD. Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases. *Int J Cardiol*.2006;111(3):365-70.
62. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes.1984;85(6): 751–8.

63. Ferrari K, Goti P, Misuri G. Chronic exertional dyspnea and respiratory muscle function in patients with chronic obstructive pulmonary disease. *Lung*. 1997;175(5):311-9.
64. Shah YM, Xie L. Hypoxia-inducible factors link iron homeostasis and erythropoiesis. *Gastroenterology*. 2014;146:630-42.
65. Chambellan A, Coulon S, Cavailles A, Hermine O, Similowski T. COPD and erythropoiesis: Interactions and consequences. *Rev Mal Respir*. 2012;29:213-31.
66. Weiss G, Goodnough LT. Anemia of chronic disease. *N Engl J Med*. 2005;352:1011-23.
67. Roy CN. Anemia of inflammation. *Hematology Am Soc Hematol Educ Program*. 2010;2010:276-80.
68. Poggiali E, Migone De Amicis M, Motta I. Anemia of chronic disease: A unique defect of iron recycling for many different chronic diseases. *Eur J Intern Med*. 2014;25:12-7.
69. Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz-Knappe P. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. *FEBS Lett*. 2000;480:147-50.
70. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Heparin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. *Blood*. 2003;101:2461-3.
71. Liu XB, Nguyen NB, Marquess KD, Yang F, Haile DJ. Regulation of hepcidin and ferroportin expression by lipopolysaccharide in splenic macrophages. *Blood Cells Mol Dis*. 2005;35:47-56.
72. Bekri S, Gual P, Anty R, Luciani N, Dahman M, Ramesh B. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. *Gastroenterology*. 2006;131:788-96.
73. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. *PNAS USA*. 2002;99:4596-601.

74. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. PNAS USA. 2001;98:8780-5.
75. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med. 1996;334:835-40.
76. Negi H, Sarkar M, Raval AD, Pandey K, Das P. Health-related quality of life in patients with chronic obstructive pulmonary disease in North India. J Postgrad Med. 2014;60:7-11.
77. Krishnan G, Grant BJ, Muti PC, Mishra A, Ochs-Balcom HM, Freudenheim JL, *et al.* Association between anemia and quality of life in a population sample of individuals with chronic obstructive pulmonary disease. BMC Pulm Med. 2006;6(23):1-9
78. Valderramas S, Camelier AA, Silva SA, Mallmann R, de Paulo HK, Rosa FW. Reliability of the Brazilian Portuguese version of the fatigue severity scale and its correlation with pulmonary function, dyspnea, and functional capacity in patients with COPD. J Bras Pneumol. 2013;39:427-33.
79. Cote C, Zilberberg MD, Mody SH, Dordelly LJ, Celli B. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J. 2007;29:923-9.
80. Barba R, de Casasola GG, Marco J, Emilio Losa J, Plaza S, Canora J, *et al.* Anemia in chronic obstructive pulmonary disease: A readmission prognosis factor. Curr Med Res Opin. 2012;28:617-22.
81. Martinez-Rivera C, Portillo K, Muñoz-Ferrer A, Martínez-Ortiz ML, Molins E, Serra P, *et al.* Anemia is a mortality predictor in hospitalized patients for COPD exacerbation. COPD. 2012;9:243-50.
82. Chambellan A, Chailleux E, Similowski T; ANTADIR Observatory Group. Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. 2005;128:1201-8.
83. Schönhofer B, Wenzel M, Geibel M, Köhler D. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive

- pulmonary disease. Crit Care Med.1998;26:1824-8.
84. Muthmainnah, Restuastuti T, Munir SM. Gambaran Kualitas Hidup Pasien PPOK Stabil Di Poli Paru Rsud Arifin Achmad Provinsi Riau Dengan Menggunakan Kuesioner SGRQ. JOM FK. 2015;2(2):1-20
 85. Yulputri N. Hubungan Anemia dengan Skala mMRC [Tesis].Padang:Fakultas Kedokteran Universitas Andalas;2016
 86. Panamotan Sidabutar, Rasmaliah, Hiswani. Karakteristik Penderita Penyakit Paru Obstruksi Kronik (PPOK) yang dirawat Inap di RSUP H. Adam malik Medan Tahun 2012. Jurnal Usu.2013;2(2):1-14
 87. Pandey S, Garg R, Kant S, Gaur P. Chronic Obstructive Pulmonary Disease with Anemia as Comorbidity in North Indian Population. Adv Biomed Res. 2018;7:152-72
 88. Selvam, Pannir R. Gambaran Karakteristik (Faktor Risiko, Gejala Klinis/Riwayat Pengobatan, dan Pemeriksaan Spirometri), Pasien Penyakit Paru Obstruktif Kronik (PPOK) yang Berobat ke Rumah Sakit dr Pirngadi dan RS Haji Adam Malik, Medan Tahun 2016 – 2017 [Skripsi]. Medan:Universitas Sumatera Utara;2018
 89. Putcha N, Fawzy A, Paul GG, Lambert AA, Psoter KJ, Sidhaye VK, et al. Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS. Annals ATS. 2018 Jun;15(6):710–7.
 90. Ozyilmaz E, Kokturk N, Teksut G, Tatlicioglu T. Unsuspected risk factors of frequent exacerbations requiring hospital admission in chronic obstructive pulmonary disease. Int J Clin Pract. 2013;67(7):691–7.
 91. Houben-Wilke S, Janssen DJA, Franssen FME, Vanfleteren LEGW, Wouters EFM, Spruit MA. Contribution of individual COPD assessment test (CAT) items to CAT total score and effects of pulmonary rehabilitation on CAT scores. Health Qual Life Outcomes. 2018;16(1):205-13
 92. Boutou AK, Stanopoulos I, Pitsiou GG. Anemia of chronic disease in chronic obstructive pulmonary disease: a case-control study of cardiopulmonary

exercise responses. *Respiration* 2011; 82: 237–45

